

22. August. 2023

## Awarded "The Japan Medical Research and Development Start-up Encouragement Prize"

Ai-BrainScience Inc. (Office: Osaka, CEO; Kentaro Takamura, Ph.D., "the company" hereinafter) announce that the company received from the Japan Cabinet Office "The Japan Medical Research and Development Start-up Encouragement Prize" for developing the eye-tracking-based cognitive assessment as Medical Dx.

The Japan Medical Research and Development Grand Prize has been established to recognize achievements in promoting research and development in the medical field, thereby deepening public interest and understanding, and incentivizing researchers. The Award was launched in 2009 and is now in its 6<sup>th</sup> year. This year, a new startup category has been added to recognize startup companies with promising prospects in the medical R&D.

## **Prize Content**

Prize	6 <sup>th</sup> Japan Medical Research and Development Grand Prize
	Startup Encouragement Prize
Title	[Medical Dx]
	Development of Eye-Tracking based Cognitive Assessment Application
Achievement	The company develop the cognitive assessment application using patients
	'gaze data as "Software as Medical Device" to deal with the social challenges
	of dementia. The technology will help identify more patients with cognitive
	decline at earlier stage and accelerate further prevention. Also, the technology
	will reduce both the patients' mental stress and the capacity of medical staff.
Overview	There is a clinical bottleneck in dementia diagnosis, because the
	conventional questionnaire-based cognitive assessment has several
	problems including "inflicting mental stress on patients", "lengthy time
	over 15 minutes", and "score vary depend on physicians".
	<ul> <li>The eye-tracking based technology will provide objective cognitive</li> </ul>
	assessment using patients' gaze data within 3 minutes. In addition,
	the technology is designed to cause much less mental stress on patients
	because their answer is unknown during the assessment whether it is

correct or wrong. Also, the assessment score will not vary because the
technology is independent of physicians' experience and skills.
• The technology can take advantages of language-independence so that
the software can be used globally.

The company will continue to develop products that satisfy unmet needs in the medical field.

<Cite>

The Japan Medical Research and Development Grand Prize: https://www.kantei.go.jp/jp/singi/kenkouiryou/pdf/kaihatsu\_taishou\_6.pdf

<Media Contact> Ai-BrainScience Inc. TEL:+81-3-6272-6744 e-Mail:info@ai-brainscience.co.jp URL:<u>https://www.ai-brainscience.co.jp/en/</u>